Cargando…

Cost‐Effectiveness of Intensifying Lipid‐Lowering Therapy With Statins Based on Individual Absolute Benefit in Coronary Artery Disease Patients

BACKGROUND: A validated prediction model estimates the absolute benefit of intensive versus standard lipid‐lowering therapy (LLT) with statins on next major cardiovascular events for individual patients with coronary artery disease. We aimed to assess whether targeting intensive LLT therapy to coron...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stam‐Slob, Manon C., van der Graaf, Yolanda, Greving, Jacoba P., Dorresteijn, Jannick A.N., Visseren, Frank L.J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5523762/ https://www.ncbi.nlm.nih.gov/pubmed/28214794 http://dx.doi.org/10.1161/JAHA.116.004648

Ejemplares similares

Would treatment decisions about secondary prevention of CVD based on estimated lifetime benefit rather than 10-year risk reduction be cost-effective?
por: Berkelmans, Gijs F. N., et al.
Publicado: (2020)

Personalized absolute benefit of statin treatment for primary or secondary prevention of vascular disease in individual elderly patients
por: Stam-Slob, Manon C., et al.
Publicado: (2016)

Use of lipid-lowering therapy after ischaemic stroke and expected benefit from intensification of treatment
por: Gynnild, Mari Nordbø, et al.
Publicado: (2022)

Variation in minimum desired cardiovascular disease-free longevity benefit from statin and antihypertensive medications: a cross-sectional study of patient and primary care physician perspectives
por: Jaspers, Nicole E M, et al.
Publicado: (2018)

Impact of a Patient’s Baseline Risk on the Relative Benefit and Harm of a Preventive Treatment Strategy: Applying Trial Results in Clinical Decision Making
por: de Vries, Tamar I., et al.
Publicado: (2021)

Communicating personalised statin therapy-effects as 10-year CVD-risk or CVD-free life-expectancy: does it improve decisional conflict? Three-armed, blinded, randomised controlled trial
por: Jaspers, Nicole E M, et al.
Publicado: (2021)

Aanpak van langdurige klachten na COVID-19
por: Otto, Fleur, et al.
Publicado: (2022)

The daily 10 kcal expenditure deficit: a before-and-after study on low-cost interventions in the work environment
por: Dorresteijn, Johannes A N, et al.
Publicado: (2013)

Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease
por: Schlackow, Iryna, et al.
Publicado: (2019)

Intensified lipid-lowering treatment with alirocumab in patients with coronary heart disease
por: Steffens, Daniel, et al.
Publicado: (2021)

Actions of metformin and statins on lipid and glucose metabolism and possible benefit of combination therapy
por: van Stee, Mariël F., et al.
Publicado: (2018)

Pleiotropic and Lipid–lowering Effects of Statins in Hypertension
por: Kamberi, Lulzim Selim, et al.
Publicado: (2012)

Lipid-lowering drugs (statins) and peripheral neuropathy
por: Emad, Mohammadreza, et al.
Publicado: (2018)

Potent anti-ischaemic effects of statins in chronic stable angina: incremental benefit beyond lipid lowering?
por: Deanfield, John E., et al.
Publicado: (2010)

Effect of Switching From Statin Monotherapy to Ezetimibe/Simvastatin Combination Therapy Compared With Other Intensified Lipid‐Lowering Strategies on Lipoprotein Subclasses in Diabetic Patients With Symptomatic Cardiovascular Disease
por: Le, Ngoc‐Anh, et al.
Publicado: (2015)

Cardiovascular risk factor treatment targets and renal complications in high risk vascular patients: a cohort study
por: Selvarajah, Sharmini, et al.
Publicado: (2011)

The relation between body fat distribution, plasma concentrations of adipokines and the metabolic syndrome in patients with clinically manifest vascular disease
por: Schrover, Ilse M, et al.
Publicado: (2018)

Glycaemic Effects of Non-statin Lipid-Lowering Therapies
por: Collins, Patrick D., et al.
Publicado: (2016)

Statins and the Brain: More than Lipid Lowering Agents?
por: Fracassi, Anna, et al.
Publicado: (2019)

Pleiotropic use of Statins as non-lipid-lowering drugs
por: Zhang, Qijia, et al.
Publicado: (2020)

Lower Intensified Target LDL-c Level of Statin Therapy Results in a Higher Risk of Incident Diabetes: A Meta-Analysis
por: Cai, Rongrong, et al.
Publicado: (2014)

Cost-effectiveness of Ezetimibe plus statin lipid-lowering therapy: A systematic review and meta-analysis of cost-utility studies
por: Sasidharan, Akhil, et al.
Publicado: (2022)

Identifying treatment response to antihypertensives in patients with obesity-related hypertension
por: Schrover, Ilse M., et al.
Publicado: (2017)

Beyond lipid lowering: pleiotropic effects of statins in heart failure
por: Swenne, C. A.
Publicado: (2013)

Effectiveness and safety of combinational therapy compared with intensified statin monotherapy in patients with coronary heart disease
por: Liu, Chenghua, et al.
Publicado: (2018)

Should We Intensify Statin Management in ACS Patients with Very Low LDL Cholesterol Levels?
por: Han, Ki Hoon
Publicado: (2019)

Statin therapy and lipids-lowering supplements – safe and effective treatment of lipids disturbances in children
por: Grabarczyk, Małgorzata, et al.
Publicado: (2022)

Treatment of hypercholesterolaemia in older adults calls for a patient-centred approach
por: Kleipool, Emma EF, et al.
Publicado: (2020)

Adherence to Lipid-Lowering Treatment by Single-Pill Combination of Statin and Ezetimibe
por: Rea, Federico, et al.
Publicado: (2021)

Beyond Lipid-Lowering: Effects of Statins on Cardiovascular and Cerebrovascular Diseases and Cancer
por: Morofuji, Yoichi, et al.
Publicado: (2022)

Consistency of effect of ezetimibe/simvastatin compared with intensified lipid-lowering treatment strategies in obese and non-obese diabetic subjects
por: Rosen, Jeffrey B, et al.
Publicado: (2013)

Insulin resistance increases the occurrence of new cardiovascular events in patients with manifest arterial disease without known diabetes. The SMART study
por: Verhagen, Sandra N, et al.
Publicado: (2011)

A new selection method to increase the health benefits of CVD prevention strategies
por: Lagerweij, Ghizelda R, et al.
Publicado: (2018)

Intensified low-density lipoprotein-cholesterol target of statin therapy and cancer risk: a meta-analysis
por: Sun, Haixia, et al.
Publicado: (2015)

Intensified synthesis of palm olein designer lipids using sonication
por: Jadhav, Harsh B., et al.
Publicado: (2021)

Lipid-lowering therapy: who can benefit?
por: Lewis, Sandra J
Publicado: (2011)

Genome-Wide Association of Lipid-Lowering Response to Statins in Combined Study Populations
por: Barber, Mathew J., et al.
Publicado: (2010)

New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins
por: Kim, Kyuho, et al.
Publicado: (2022)

New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins
por: Kim, Kyuho, et al.
Publicado: (2022)

Statins: benefits and risks revisited
por: Balaz, Miroslav, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_calburmkb8mvakck0pqldmo1ic